Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 21, 2010
Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapyVinod Rustgi, David R Nelson, Vijayan Balan, et al.Journal of Hepatology|May 19, 2009
Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis CAvidan U Neumann, Stephen Pianko, Stefan Zeuzem, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2008
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patientsVincent G Bain, Kelly D Kaita, Paul Marotta, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 7, 2011
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3Samir R Shah, Keyur Patel, Patrick Marcellin, et al.Hepatology (Baltimore, Md.)|July 31, 2008
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis CStefan Zeuzem, Eric M Yoshida, Yves Benhamou, et al.World Journal of Gastroenterology|December 8, 2011
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virusKeyur Patel, Mireen Friedrich-Rust, Yoav Lurie, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 9, 2008
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis CDavid R Nelson, Vinod Rustgi, Vijayan Balan, et al.Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.Gastroenterology|April 10, 2017
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a StudyBruce E Sands, Jingjing Chen, Brian G Feagan, et al.Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3David R Nelson, Yves Benhamou, Wan-Long Chuang, et al.Pageof 3